Foghorn co-founder Cigall Kadoch resigns from board after HHMI appointment; stays as scientific advisor

Foghorn Therapeutics Inc.

Cigall Kadoch resigned from Foghorn's Board of Directors effective August 31, 2022.
Resignation due to her appointment as HHMI Investigator; no disagreement with the company.
Kadoch transitions to role of Scientific Advisor to the Board and remains on Scientific Advisory Board.
Co-founder and former board member will continue to advise the company on chromatin regulatory system.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Cigall Kadoch

member of the Board of Directors

FHTX · Foghorn Therapeutics Inc.

Effective: 2022-08-31
Filed: August 31, 2022, 7:59 PM ET

On August 31, 2022, Cigall Kadoch, Ph.D., resigned from her position as a member of the Board of Directors of Foghorn Therapeutics Inc. (the “Company”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cigall Kadoch resigned as member of the Board of Directors at Foghorn Therapeutics Inc..

Action: resigned
Role: member of the Board of Directors

Exact text from the filing

On August 31, 2022, Cigall Kadoch, Ph.D., resigned from her position as a member of the Board of Directors of Foghorn Therapeutics Inc. (the “Company”), effective immediately.

View on SEC.gov

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-024056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.